Raul R. Rodriguez - Jan 24, 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
CEO, President, Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Jan 24, 2025
Transactions value $
-$28,419
Form type
4
Date filed
1/28/2025, 08:49 PM
Previous filing
Nov 26, 2024
Next filing
Jan 31, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Options Exercise $963K +45K +21.99% $21.40 250K Jan 24, 2025 Direct F1, F2
transaction RIGL Common Stock Tax liability -$977K -44.1K -17.66% $22.17 206K Jan 24, 2025 Direct
transaction RIGL Common Stock Options Exercise $963K +45K +21.89% $21.40 251K Jan 24, 2025 Direct F1
transaction RIGL Common Stock Tax liability -$977K -44.1K -17.59% $22.17 207K Jan 24, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -45K -100% $0.00 0 Jan 24, 2025 Common Stock 45K $21.40 Direct F1, F3
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -45K -100% $0.00 0 Jan 24, 2025 Common Stock 45K $21.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2 Includes 1,000 shares acquired under the Issuer's stock purchase plan.
F3 The shares vested monthly over two (2) years from January 1, 2015.